|Bid||34.41 x 800|
|Ask||34.42 x 3300|
|Day's Range||34.39 - 34.67|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||25.78|
|Dividend & Yield||1.90 (5.41%)|
|1y Target Est||N/A|
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.
The agenda was dominated by eurozone economic data, the anniversary of Britain's vote to leave the EU and a political summit in Brussels on Friday.
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.